Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.3.1.900
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Revenue:      
Lymphoseek sales revenue $ 10,254,352 $ 4,233,953 $ 614,423
Lymphoseek license revenue 1,133,333 300,000  
Grant and other revenue 1,861,622 1,740,896 516,207
Total revenue 13,249,307 6,274,849 1,130,630
Cost of goods sold 1,754,763 1,586,145 332,815
Gross profit 11,494,544 4,688,704 797,815
Operating expenses:      
Research and development 12,787,733 16,779,589 23,710,183
Selling, general and administrative 17,257,329 15,542,071 15,525,946
Total operating expenses 30,045,062 32,321,660 39,236,129
Loss from operations (18,550,518) (27,632,956) (38,438,314)
Other income (expense):      
Interest expense, net (6,873,736) (3,690,068) (2,759,942)
Equity in loss of R-NAV, LLC (305,253) (523,809)  
Change in fair value of financial instruments (614,782) (1,342,389) (112,073)
Loss on extinguishment of debt (2,440,714) (2,610,196) (1,372,266)
Other, net 26,808 72,749 (16,863)
Total other expense, net (10,207,677) (8,093,713) (4,261,144)
Loss before income taxes (28,758,195) (35,726,669) (42,699,458)
Benefit from income taxes 436,051    
Loss from continuing operations (28,322,144) (35,726,669) (42,699,458)
Income from discontinued operations, net of tax effect 758,609    
Net loss (27,563,535) (35,726,669) (42,699,458)
Less loss attributable to noncontrolling interest (855)    
Deemed dividend on beneficial conversion feature of MT Preferred Stock (46,000)    
Net loss attributable to common stockholders $ (27,608,680) $ (35,726,669) $ (42,699,458)
Income (loss) per common share (basic and diluted):      
Continuing operations $ (0.19) $ (0.24) $ (0.35)
Discontinued operations 0.01    
Attributable to common stockholders $ (0.18) $ (0.24) $ (0.35)
Weighted average shares outstanding (basic and diluted) 151,180,222 148,748,396 121,808,986